Phase 1 safety and immunogenicity evaluation of ADMVA, a multigenic, modified vaccinia Ankara-HIV-1 B'/C candidate vaccine.

Phase 1 safety and immunogenicity evaluation of ADMVA, a multigenic, modified vaccinia Ankara-HIV-1 B'/C candidate vaccine.

We conducted a Phase I dose-escalation trial of ADMVA, a Clade-B'/C-based HIV-1 candidate vaccine expressing env, gag, pol, nef, and tat in a modified vaccinia Ankara viral vector. Sequences were derived from a prevalent circulating HIV-1 recombinant form in Yunnan, China, an area of high HIV i...

Full description

Bibliographic Details
Main Authors: Sandhya Vasan, Sarah J Schlesinger, Zhiwei Chen, Arlene Hurley, Angela Lombardo, Soe Than, Phumla Adesanya, Catherine Bunce, Mark Boaz, Rosanne Boyle, Eddy Sayeed, Lorna Clark, Daniel Dugin, Mar Boente-Carrera, Claudia Schmidt, Qing Fang, LeiBa, Yaoxing Huang, Gerasimos J Zaharatos, David F Gardiner, Marina Caskey, Laura Seamons, Martin Ho, Len Dally, Carol Smith, Josephine Cox, Dilbinder Gill, Jill Gilmour, Michael C Keefer, Patricia Fast, David D Ho
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2010-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC2810329?pdf=render

Internet

http://europepmc.org/articles/PMC2810329?pdf=render

Similar Items